DexCom Inc
Change company Symbol lookup
Select an option...
DXCM DexCom Inc
LOW Lowe's Companies Inc
BAC Bank of America Corp
ECF Ellsworth Growth and Income Fund Ltd
EBF Ennis Inc
EARN Ellington Residential Mortgage REIT
DXC DXC Technology Co
DX Dynex Capital Inc
DVYE iShares Emerging Markets Dividend ETF
DUK Duke Energy Corp
Go

Health Care : Health Care Equipment & Supplies | Large Cap Growth
Company profile

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

Closing Price
$312.55
Day's Change
-0.77 (-0.25%)
Bid
--
Ask
--
B/A Size
--
Day's High
320.14
Day's Low
311.01
Volume
(Below Average)
Volume:
817,837

10-day average volume:
990,977
817,837

Company Profile

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

Valuation Ratios

Price/Earnings (TTM)
132.93x
Price/Sales (TTM)
16.94x
Price/Book (MRQ)
20.56x
Price/Cash Flow (TTM)
105.56x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

November 2020
Current Month
2.7M
Previous Month
2.7M
Percent of Float
2.86%
Days to Cover
2.4423 Days

Share Information

DXCM is in a share class of common stock
Float
95.7M
Shares Outstanding
96.0M
Institutions Holding Shares
1,012
94.22%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Kevin R. SayerChmn.
  • Quentin S. BlackfordCFO
  • Jake Steven LeachExec.VP
  • Donald M. AbbeyExec.VP
  • Andrew K. BaloExec.VP

Address

Insider Trading

During the most recent quarter, 209K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.